multiplicity

[키워드] 95% CI adjusted Admission adverse event adverse events age Analysis antibiotic Anticoagulants Antiviral agents ARD assigned Bayesian C-reactive protein Care clinical clinical status clinical trial clinically conducted Consent coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 COVID-19 pneumonia credible interval CrI death determine did not reduce died discharge Effect Efficacy elevated Factor Fewer patients Follow-up France greater hazard ratio Health Organization hyperinflammation Identifier IMPROVE indicated intensive care intensive care unit intention-to-treat basis interleukin-6 interquartile range intravenously investigator-initiated less mechanical ventilation median moderate moderate-to-severe COVID-19 pneumonia Mortality multicenter multiplicity NIV no difference Noninvasive ventilation occurred Open-label outcome overall survival oxygen oxygen supply oxygen support Patient patients patients hospitalized patients with COVID-19 performed Pneumonia posterior probability Primary outcomes randomized clinical trial Randomly receive recruited reduced risk risk difference scale secondary Secondary outcomes Serious Adverse Events severe pneumonia survival TCZ threshold Tocilizumab treat university hospital usual care usual care alone vasopressor support Ventilation WHO-CPS women World Health Organization
[DOI] 10.1001/jamainternmed.2020.6820 PMC 바로가기 [Article Type] Randomized Controlled Trial